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BACKGROUND: Loco-regional spread of disease causes
high morbidity and is associated with the poor prognosis
of malignant oral tumors. Better understanding of
mechanisms underlying the establishment of lymph node
metastasis is necessary for the development of more
effective therapies for patients with oral cancer. The aims
of this work were to evaluate a possible correlation
between endothelial cell Bcl-2 and lymph node metastasis
in patients with oral squamous cell carcinoma (OSCC),
and to study signaling pathways that regulate Bcl-2
expression in lymphatic endothelial cells.
METHODS: Endothelial cells were selectively retrieved
from paraffin-embedded tissue sections of primary
human OSCC from patients with or without lymph node
metastasis by laser capture microdissection. RT-PCR was
used to evaluate Bcl-2 expression in tumor-associated
endothelial cells and in tumor cells. In vitro, mechanistic
studies were performed to examine the effect of vascular
endothelial growth factor (VEGF)-C on the expression of
Bcl-2 in primary human lymphatic endothelial cells.
RESULTS: We observed that Bcl-2 expression is upreg-
ulated in the endothelial cells of human oral tumors with
lymph node metastasis as compared to endothelial cells
from stage-matched tumors without metastasis. VEGF-C
induced Bcl-2 expression in lymphatic endothelial cells via
VEGFR-3 and PI3k ⁄Akt signaling. Notably, OSCC cells
express VEGF-C and induce Bcl-2 in lymphatic endothe-
lial cells.
CONCLUSIONS: Collectively, this work unveiled a
mechanism for the induction of Bcl-2 in lymphatic endo-
thelial cells and suggested that endothelial cell Bcl-2
contributes to lymph node metastasis in patients with
oral squamous cell carcinoma.
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Introduction
The crosstalk between neovascular endothelial cells and
tumor cells plays a major role in oral squamous cell
carcinoma (OSCC) tumor growth and angiogenesis
(1–3). We have reported that Bcl-2 is a key regulator
of this crosstalk (1, 2) and have reported a novel role for
Bcl-2 as a pro-angiogenic signaling molecule (4). How-
ever, the functional implications of the molecular
interactions between lymphatic endothelial cells and
OSCC cells are not clearly understood. Considering that
OSCC frequently metastasize to the lymph nodes, a
better understanding of the crosstalk between lymphatic
endothelial cells and OSCC may lead to new therapies
and to signiﬁcant improvements in the management of
patients with oral cancer.
It has been reported that vascular endothelial growth
factor (VEGF)-C and its cognate receptor VEGFR-3
are expressed in head and neck squamous cell carcino-
mas (5). VEGF-C binds primarily to VEGFR-3, induc-
ing lymphangiogenesis (6) and regulating several cellular
functions involved in cancer progression (5, 7–9). Once
activated, VEGFR-3 is phosphorylated and triggers
signaling through the PI3k ⁄Akt pathway (10, 11). The
activation of the PI3k ⁄Akt pathway can induce Bcl-2
expression in vascular endothelial cells (12). However,
the role of the PI3k ⁄Akt pathway in the regulation of
VEGF-C-induced Bcl-2 expression in lymphatic endo-
thelial cells remains unclear.
This study was designed to examine signaling path-
ways involved in the regulation of Bcl-2 in lymphatic
endothelial cells, and to evaluate the impact of endo-
thelial cell Bcl-2 expression in primary tumors on lymph
node metastasis. Our results suggest that Bcl-2 expres-
sion levels in primary tumor-associated endothelial
cells are correlated with the incidence of lymph node
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metastasis in patients with OSCC. Furthermore, this
work revealed that VEGF-C induces Bcl-2 expression in
lymphatic endothelial cells via VEGFR-3 signaling
through the PI3k ⁄Akt pathway.
Materials and methods
Cell culture
Primary human dermal lymphatic microvascular endo-
thelial cells (HMVEC) and human dermal microvascu-
lar endothelial cells (HDMEC) were obtained from
Lonza (Walkersville, MD, USA) and cultured in EGM-
2 MV (Lonza). The human oropharyngeal SCC cell lines
(UM-SCC-11A, UM-SCC-11B, UM-SCC-17A, gift
from Dr. T. Carey, University of Michigan) were
cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% fetal bovine serum and penicil-
lin ⁄ streptomycin.
Western blots
VEGF-C and VEGFR-3 baseline expression levels were
evaluated by Western blots using polyclonal anti-human
VEGF-C and anti-human VEGFR-3 antibodies, respec-
tively (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Furthermore, HMVEC and HDMEC were
serum-starved overnight, pretreated with 0–30 lM
LY294002 (Sigma-Aldrich, St. Louis, MO, USA) for
1 h, and then treated with 0–50 ng ⁄ml rhVEGF-C (R &
D Systems, Minneapolis, MN, USA) for 24 hours in the
presence of LY2964002. Alternatively, HMVEC were
exposed to serum-free conditioned media collected from
the SCC cell lines for 24 h. The role of VEGFR-3 in
VEGF-C-induced Bcl-2 expression was evaluated with
0–10 lg ⁄ml anti-human VEGFR-3 neutralizing anti-
body (Santa Cruz). Bcl-2 expression was evaluated by
Western blot with the hamster anti-human Bcl-2 (BD
Biosciences, San Jose, CA, USA), and phosphorylated
and total Akt expression was also analyzed with
respective polyclonal anti-human antibodies (Cell Sig-
naling, Beverly, MA, USA).
LCM and RT-PCR from human OSCC
Six cases of OSCC with known clinical outcomes were
studied here (Table 1). They included three metastatic
(M+ OSCC) and three non-metastatic (M) OSCC)
tumors. The limited number of cases in each group is
explained by the fact that the samples included in this
study strictly met the following inclusion criteria: (A)
they should be retrieved from patients who had surgical
neck resection and lymph node immunohistochemical
conﬁrmation with analysis for cytokeratins (Fig. 1); and
(B) the laser capture microdissection (LCM)-retrieval
should generate at least 1500 endothelial cells and
10 000 tumor cells located exclusively in the advancing
tumor front. Immunohistochemical staining for Factor
VIII (1:500; Neomarkers, Fremont, CA, USA) was
performed to identify vascular endothelial cells in
preparation for the LCM, as described (1). Endothelial
cells and tumor cells were retrieved from each tissue
section from the three independent tumors and pooled
for RT-PCR analysis according to each experimental
condition. Total RNA was isolated using Trizol reagent
(Invitrogen) and puriﬁed with RNAeasy Mini Kits
(Qiagen Inc., Valencia, CA, USA). SuperScript one-step
reverse-transcription-PCR (RT-PCR) was performed
using the Platinum Taq kit (Invitrogen). The following
are the primer sequences: E-cadherin (sense 5¢-TGGAC
AGGGAGGATTTTGAG-3¢; antisense 5¢-CTTGAGC
CCCAGAGTTTGAG-3¢; 385 bp amplicon); Bcl-2
(sense 5¢-CTGCGAAGAACCTTGTGTGA-3¢; anti-
sense 5¢-TGTCCCTACCAACCAGAAGG-3¢; 214 bp
amplicon); and GAPDH sense 5¢-CATGGCCTCCAA
GGAGTAAG-3¢; antisense 5¢-AGGGGTCTACAGGC
AACTG-3¢; 683 bp).
Results
Bcl-2 expression in the endothelial cells of metastatic
tumors
A stepwise method was used to selectively retrieve
endothelial cells or OSCC cells from paraﬃn-embedded
tissue sections (Fig. 2). The ﬁrst step aims at the
elimination of luminal contents (Fig. 2B). This is
followed by retrieval of tumor-associated endothelial
cells (Fig. 2C), and retrieval of tumor cells (Fig. 2D).
This method results in a relatively pure RNA prepara-
tion, as demonstrated by the analysis of E-cadherin
expression, a well-known marker for cells with epithelial
origin (Fig. 2E,F; Fig. S1). Indeed, while the tumor cell
RNA preparations showed strong positive expression of
E-cadherin, the endothelial cell RNA preparations did
not. Once the purity of the RNA preparations was
conﬁrmed, we evaluated Bcl-2 expression levels in the
endothelial cells of tumors from patients with or without
lymph node metastasis. We observed that Bcl-2 was
Table 1 Personal data, staging, histological grade, and number of metastatic lymph nodes in the oral squamous cell carcinoma cases evaluated
here. These tumors were located in the tongue and ⁄ or ﬂoor of the mouth, as determined by clinical and histological evaluation
Patient Personal data TNM Histological grade LN involvement (number of lymph nodes)
M(+)1 Male, White, 58 years old T2N2M0 I L2 (2), L3 (2), L4 (2)
M(+)2 Male, White, 61 years old T2N1M0 III L2 (4)
M(+)3 Male, White, 69 years old T4N2aM0 III RL1 (3), RL2 (3), RL3 (1); LL1 (2), LL2 (4)
M())1 Female, White, 63 years old T2N0M0 II None
M())2 Male, White, 48 years old T4aN0M0 III None
M())3 Male, White, 62 years old T2N0M0 III None
RL, right side and level; LL, left side and level; L, level.
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Figure 1 Histopathological and immunohistochemical features of an oral squamous cell carcinoma with lymph node metastasis. (A–B)
Representative tumor front of a primary M+ OSSC case evaluated here (A – HE, 100·; B – HE, 200·). (C–D). Lymph node metastasis of OSSC
showing a nest of malignant keratinocytes (C – HE, 100·) positive for AE1 ⁄AE3 antibody (D – AE1 ⁄AE3, 200·).
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Figure 2 Bcl-2 is expressed in tumor-associated endothelial cells of metastatic human oral squamous cell carcinomas (OSCC). (A–D) Step-by-step
characterization of the technique used for retrieval of either tumor cells or endothelial cells from parafﬁn-embedded tissue sections by laser capture
microdissection (LCM). (E) RT-PCR analysis of Bcl-2 and E-cadherin expression in the endothelial cells of metastatic (M+) or non-metastatic
(M)) OSCC. (F) RT-PCR analysis of Bcl-2 and E-cadherin expression in the tumor cells of metastatic (M+) or non-metastatic (M)) OSCC. (E,F)
Controls were vascular endothelial cells captured by LCM from normal oral mucosa (EC, oral mucosa), human dermal microvascular endothelial
cells (HDMEC), and human cervical cancer cell line (HeLa).
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strongly expressed in tumor-associated endothelial cells
of patients with metastasis, but not in patients without
metastasis (Fig. 2E). Interestingly, Bcl-2 expression was
undetectable in the OSCC cells (Fig. 2F).
VEGF-C signals through VEGFR-3 to induce Bcl-2 in
lymphatic endothelial cells
To understand potential mechanisms regulating Bcl-2 in
lymphatic endothelial cells, we studied the activity of the
VEGF-C and VEGFR-3 signaling pathways. While
lymphatic endothelial cells strongly express VEGFR-3,
vascular endothelial cells and three OSCC cell lines did
not express this receptor (Fig. 3A). In contrast, all cells
examined here expressed VEGF-C (Fig. 3A). Bcl-2
expression was potently induced by rhVEGF-C in
lymphatic endothelial cells (Fig. 3B). The growth factor
milieu secreted by OSCC potently induced Bcl-2 expres-
sion in lymphatic endothelial cells (Fig. 3C). Notably,
VEGF-C-induced Bcl-2 expression is mediated by
VEGFR-3 signaling in lymphatic endothelial cells
(Fig. 3D).
Akt mediates VEGF-C-induced Bcl-2 expression in
lymphatic endothelial cells
To evaluate the role of Akt on the regulation of Bcl-2
expression in lymphatic endothelial cells, we used
LY294002, an inhibitor of the PI3k-Akt signaling.
VEGF-C induced rapid and potent phosphorylation of
Akt in lymphatic endothelial cells (Fig. 4A). As
expected, LY294002 blocked VEGF-C-induced Akt
phosphorylation in these cells (Fig. 4A). Blockade of
Akt phosphorylation abrogated VEGF-C-induced Bcl-2
expression in lymphatic endothelial cells, demonstrating
the requirement of Akt signaling in this process
(Fig. 4B). In contrast, VEGF-C had no eﬀect on Akt
phosphorylation and Bcl-2 expression in dermal endo-
thelial cells (Fig. 4A,B).
Discussion
It is well known that the control of loco-regional disease
constitutes a major challenge in the management of
patients with oral cancer. A complicating factor is that
very little is known about the mechanisms underlying
the displacement of OSCC from the primary tumor site
and the beginning of the cellular processes that result in
lymph node metastasis. Lymphatic vessels can be found
within certain cancer types (13, 14). Notably, emerging
evidence has shown that cancer cells invade into local
lymph nodes mainly via peritumoral lymphatic vessels
(15). It has been recently shown that the crosstalk
between cancer cells and lymphatic endothelium induces
changes in the lymphatics that may contribute to
metastatic spread (16). Indeed, lymphatic endothelial
cells activated by highly metastatic cancer cells displayed
aberrant behaviors and secrete chemokines that facili-
tate cancer cell migration (17). Here, we observed that
Bcl-2 is highly expressed in tumor-associated endothelial
cells of oral cancer patients with lymph node metastasis,
while it is undetectable in the endothelial cells of patients
that did not metastasize. These ﬁndings enhance the
understanding of mechanisms of OSCC metastasis and
may have implications to the clinical management of
patients with oral cancer.
We have previously shown that endothelial cell Bcl-2
signaling promotes head and neck tumor growth (1) and
induces tumor cell motility via the CXC chemokine
pathway (18). These ﬁndings provided the rationale for
the current exploration of the role of endothelial cell
Bcl-2 on the metastatic spread of head and neck
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Figure 3 Vascular endothelial growth factor (VEGF)-C and the growth factor milieu secreted by oral squamous cell carcinoma (OSCC) induce
Bcl-2 expression in lymphatic endothelial cells. (A) Western blot for the evaluation of baseline VEGF-C and VEGFR-3 expression in human
lymphatic endothelial cells (HMVEC), human dermal microvascular endothelial cells (HDMEC), and in three OSCC cell lines (UM-SCC-11A,
UM-SCC-11B, UM-SCC-17A); (B) Western blot to study the effect of rhVEGF-C on Bcl-2 expression in lymphatic endothelial cells. (C) Western
blot for evaluation of the effect of 24-h conditioned medium from three OSCC cells lines on Bcl-2 expression in lymphatic endothelial cells. (D)
Western blot to determine the role of VEGFR-3 on VEGF-C-induced Bcl-2 in lymphatic endothelial cells. Cells were exposed to 10 ng ⁄ml
rhVEGF-C in the presence of increasing concentrations of neutralizing anti-VEGFR3 antibody.
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squamous cell carcinomas (HNSCC). Since we found
that endothelial cell Bcl-2 expression levels were corre-
lated with lymph node metastasis, and assuming that
lymph node metastases would be primarily driven by
invasion through lymphatic vessels, we focused the
mechanistic studies included here on the analyses of
lymphatic endothelial cells, using vascular endothelial
cells as controls. We observed that all OSCC cell lines
evaluated here express VEGF-C. VEGF-C expression
has been correlated with lymphatic metastatic potential
and invasiveness of cancer cells (18–21). Zhuang et al.
have shown that VEGF-C is expressed by highly
metastatic OSCC cells (16, 17). We observed that
VEGF-C, as well as the growth factor milieu secreted
by several OSCC cell lines, induced Bcl-2 expression in
lymphatic endothelial cells. These data are in line with
the observation that VEGF-C induces the survival of
leukemic tumor cells (7). Notably, the VEGF-C ⁄VEG-
FR3 axis activation has been associated with lymphan-
giogenesis (19), angiogenesis (22), and endothelial cell
survival (23). Collectively, these observations suggest
that VEGF-C augments the lymphatic component of
oral tumors by enhancing the Bcl-2 expression in the
lymphatic endothelial cells.
It has been shown that VEGF-C activates the
PI3k ⁄Akt pathway through VEGFR3 (7, 10). Here,
we showed that VEGF-C induces Akt phosphorylation
and Bcl-2 expression in VEGFR3-expressing lymphatic
endothelial cells, but not in dermal endothelial cells that
do not express VEGFR3. These data suggest that the
eﬀects of VEGF-C on Bcl-2 are speciﬁc to the lymphatic
system. Further, we observed that signaling through
VEGFR3 and the phosphorylation of Akt are required
for Bcl-2 expression in lymphatic endothelial cells.
Collectively, these ﬁndings unveil a pathway for the
regulation of lymphatic endothelial cell survival that is
orchestrated by Bcl-2.
The gene expression analysis performed with cells
retrieved from human OSCC provides clinical relevance
to our laboratory results. Tumor-associated endothelial
cells from metastatic OSCC cases expressed Bcl-2, while
the endothelial cells from the tumors of patients that did
not exhibit metastasis did not express Bcl-2. To the best
of our knowledge, this is the ﬁrst demonstration of a
correlation between primary tumor-associated endothe-
lial cell Bcl-2 expression and the presence of lymph node
metastasis. We speculate that Bcl-2 may contribute to
the metastatic spread to lymph nodes by the following:
(i) Increasing the survival of tumor-associated endothe-
lial cells in OSCC; (ii) Triggering signaling pathways
that result in enhanced secretion of chemotactic factors
by endothelial cells; and (iii) Enhancing the invasive
phenotype of OSCC cells. Notably, we have demon-
strated that Bcl-2 induces expression of CXCL1 and
CXCL8 in vascular endothelial cells (4) and that these
factors signal through CXCR2 to enhance the invasive-
ness of head and neck squamous cell carcinoma cells
(18). Our laboratory is currently performing studies to
better understand the functional role of Bcl-2 in tumor-
associated lymphatic endothelial cells.
Taken together, our results unveiled a signaling
pathway that may have signiﬁcant implications to the
regulation of lymphangiogenesis and metastatic spread
of oral cancers (Fig. 5). These studies suggest that Bcl-2
A
B
Figure 4 Vascular endothelial growth factor (VEGF)-C induces Bcl-2 expression via PI3k ⁄Akt signaling in lymphatic endothelial cells. (A,B)
Lymphatic and dermal (vascular) endothelial cells were exposed to VEGF-C for 15 or 30 min in the presence (or absence) of the inhibitor of
PI3k ⁄Akt signaling, LY294002. (A) Western blots for the evaluation of the expression of total and phosphorylated Akt. (B) Western blot for the
evaluation of Bcl-2 expression.
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expression in the endothelial cells of primary tumors
might serve as a biomarker for predictions about the
metastatic potential of OSCC. These data also suggest
potential targets for the treatment of OSCCs. Particu-
larly, targeted therapeutic inhibition of Bcl-2 may have
the following complementary, and perhaps synergistic,
eﬀects: (i) Inhibition of lymphangiogenesis in OSCC;
(ii) Inhibition of vascular angiogenesis; and (iii) Direct
inhibition of tumor cell survival. The recent discovery
of highly potent and speciﬁc small molecule inhibitors
of Bcl-2 (24) raises the exciting possibility of using
these drugs in the management of patients with oral
cancer.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1 Purity and speciﬁcity of the RNA retrieved
from paraﬃn-embedded tissue sections. RT-PCR anal-
ysis of the expression of E-cadherin (marker of cells of
epithelial origin) and VEGFR2 (endothelial cell marker)
in the RNA prepared from the endothelial cell fraction
and from the tumor cell fraction. Controls were human
dermal microvascular endothelial cells (HDMEC), from
the University of Michigan Head and Neck Squamous
Cell Carcinoma cell line (UM-SCC-11A), and a human
cervical cancer cell line (HeLa).
Please note: Wiley-Blackwell are not responsible for
the content or functionality of any supporting materials
supplied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
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